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ABSTRACT
Purpose: We herein describe the clinical course of a consecutive series of
fulminant hepatic failure patients treated with molecular adsorbent recirculating
system, a cell-free albumin dialysis technique.
From November 2000 to September 2002, 7 adult patients age 22-61 (median 41),
one male (14.2%), and 6 females (85.7%), affected by fulminant hepatic failure,
underwent 7 courses (1 to 5 session each, six hours in duration) of extracorporeal
support using the molecular adsorbent recirculating system technique. Pre and
post treatment blood glucose, liver function tests, ammonia, arterial lactate,
electrolytes, hemodynamic parameters, arterial blood gases, liver histology,
Glasgow Coma Scale, and coagulation studies, were reviewed. No adverse side
effects like generalized bleeding on non-cardiogenic pulmonary edema, often seen
during MARS treatment, occurred in the patients included in this study.
Results: Six patients (85.7%) are currently alive and well, and one (14.2%) died.
Four patients (57%) were successfully bridged (two patients in 1 day and two
other patients in 4 days) to liver transplantation, while 2 (28.5%) recovered fully
without transplantation. All the measured variables stabilized after molecular
adsorbent recirculating system commencement. No differences were noted
between the pre and post molecular adsorbent recirculating system liver histology.
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Conclusions: Molecular adsorbent recirculating system is a safe, temporary life
support mechanism for patients awaiting liver transplantation or recovering from
fulminant hepatic failure.

Key words:

Albumin, dialysis, extracorporeal liver assist device,
fulminant hepatitis
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INTRODUCTION
Molecular adsorbent recirculating system (MARS) (Teraklin, Aktiengesellschaft,
Rostok, Germany) is an artificial liver support system, first introduced into
clinical practice in 1993 [1]. In contrast to bio-artificial liver support systems,
which replace some of the metabolic and synthetic functions of the liver by
means of established hepatocyte or hepatoblastoma cell lines [2], MARS aims
only at clearing the blood from metabolic waste products normally metabolized
by the liver. It is, essentially, a modified dialysis system, employing an albumincontaining dialysate that is recirculated and perfused in-line through charcoal and
anion exchanger columns. This effects the removal of albumin-bound toxins like
aromatic amino acids and their metabolites, conjugated bilirubin, bile acids,
phenols, short and middle chain fatty acids, copper, mercaptans, cytokines,
tryptophan, tumor necrosis factor- , interleukin-6, and diazepam together with
free solutes like ammonia, creatinine, urea that are removed by standard dialysis
[1, 3]. Most of the experience with MARS has shown specific efficacy in the
treatment of acute-on-chronic hepatic failure, where it improves cerebral blood
flow, hemodynamic status, liver and renal function, survival [4-6], and intractable
pruritus [7]. Molecular adsorbent recirculating system maintains electrolytes
homeostasis [8] may worsen coagulopathy [9] and be the cause non-cardiogenic
pulmonary edema [10].
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Fulminant hepatic failure (FHF) is defined as acute encephalopathy and
coagulopathy in the setting of acute liver disease where altered mental status
develops within 8 weeks from the onset of the illness in a person without
antecedent liver disease [11]. Mortality rate in course of acuteliver failure is
reported to be greater than 70% [12-13]. Liver transplantation (LTx) is a well
accepted therapy for FHF [14]. However, due to lack of organ availability it is
not always possible to transplant patients with FHF. Therefore, several different
types of supporting systems (artificial liver/bio-artificial liver) have been
developed to bridge these patients to LTx or, if possible promote spontaneous
recovery [2, 15-20].
Molecular adsorbent recirculating system has been used in course of FHF [21];
however, changes in liver histology and its correlation with Glasgow Coma Scale
(GCS) and prothrombin time, the two major clinical indicator of disease
progression, have not been addressed before.
Fulminant hepatic failure is characterized by several biochemical derangements
such as acidosis [12], hypophosphatemia, and hypoglycemia [22]. The degree of
these derangements is, at least theoretically, related to the grade of liver necrosis.
Trans-jugular liver biopsy is the method of choice to obtain liver tissue for
histology in patients with FHF and to quantitate the degree of liver injury [23].
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METHODS
Data were retrospectively collected from a consecutive series of patients admitted
at the Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
Palermo-Italy, from November 2000 to September 2002, with FHF who
underwent MARS while awaiting LTx or recovery. Follow-up: 1155 days, range
455-1155 days. Informed consent, for MARS treatment and LTx, was obtained
from next of kin.
Seven adult patients (numbered #1 to #7), one male (14.2%) and 6 females
(85.7%), age 22 – 61 years (median 41 years), underwent 7 courses (1 to 5 session
each) of MARS. Demographics are shown in Table 1.
Patient #1 developed fulminant hepatitis B. The patient was emergently
transported to our center in stage 4 coma (Fig. 1) and died of brain herniation a
few hours before LTx.
Hepatitis B Virus (HBV) was the cause of FHF in patient # 2. The patient was
emergently transported to our center in stage 3 coma (Fig. 1) and underwent the
first LTx 5 days after the admission. The patient developed primary-non-function
and 2 days later was successfully re-transplanted. She is alive and well 38 months
after the second LTx.
Patient # 3 developed drug related (nimesulide) FHF. The patient was emergently
transported to our center awake and alert but 24 hours later went on to stage 3
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coma (Fig. 1). She was successfully transplanted 2 days following admission to
our facility. She is alive and well 24 months after LTx.
Patient # 4 developed HBV related FHF. The patient was emergently transported
to our center awake and alert and remained so, despite 95% of liver necrosis, until
the transplant, which occurred 2 days after the admission. This patient is alive
and well 23 months after LTx.
Patient # 5 developed HBV related FHF. The patient was emergently transported
to our center in stage 3 coma, underwent two LTx during the same procedure, 5
days after the admission. The first graft, a very marginal one, accepted on an
emergency base, underwent primary-non-function immediately after reperfusion,
with about 80% hepatocyte necrosis. A second cadaveric donor became available
at the time of the reperfusion of the first graft. She was, therefore, immediately
re-transplanted. She is alive and well 18 months after LTx.
Patient # 6 developed HBV related FHF. She underwent 4 MARS treatments
before showing clinical recovery from the acute event. Due to her dramatic
clinical improvement following the first MARS treatment and despite 50%
necrosis at the trans-jugular liver biopsy a decision was taken not to proceed with
the transplant. She is alive and well 16 months after the last MARS session.
Patient # 7 developed HBV related FHF. He was never placed on the waiting list
for LTx because he was diagnosed with colon cancer 12 months prior to his
evaluation. The patient was emergently transported to our center in stage 3 coma
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and underwent a total of 5 MARS treatments before showing clinical
amelioration. He is alive and well 15 months after the last MARS session.
Our pre-transplant work-up includes trans-jugular liver biopsy for those patients
fulfilling the O’Grady criteria for FHF [11] at the hospital presentation. In fact
emergent listing for LTx and treatment with MARS, while waiting for LTx, was
prompted for those patients showing 50% or more liver necrosis at liver
histology.
Exclusion criteria from MARS and/or LTx candidacy were culture-proven sepsis
and/or < 50% liver necrosis. In the intensive care unit, before starting MARS,
full patient monitoring was instituted including: central venous pressure, SwanGanz catheter placement, and systemic arterial line. Due to onsite unavailability
of technical expertise in positioning epidural probes for intracranial pressure
monitoring, this parameter was not followed.
Each course of MARS was intended to consist of seven treatment sessions, six
hours in duration (none of them had to be terminated in advance), on consecutive
days. However, none of the patients completed the prescribed course (7 sessions)
due to transplantation, death or significant clinical improvement. If a liver
became available while the patient was on MARS, the transplant was started after
the 6 hours session was completed.
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Molecular adsorbent recirculating system was performed through a hemodialysis
double-lumen catheter, as previously described [24]. Priming of the
extracorporeal circuit with heparinized saline solution (1,000 U of heparin
sulphate / liter) was carried out before MARS commencement. The
extracorporeal blood circuit was driven by a standard dialysis machine (D-85716,
Baxter, Unterschleibheim, Germany) at a flow rate of 100 ml/min initially,
increased to 200 ml/min if the patient remained hemodynamically stable.
The aim of this study was the assessment of the safety and efficacy of MARS in
patients with FHF.
During MARS therapy all patients were closely monitored for disturbances in
electrolytes, glucose level, coagulation, and blood gas exchanges. These
derangements, if present, were treated as indicated.
Pre and post-MARS blood glucose, liver function tests (total bilirubin, aspartate
aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase),
ammonia, arterial lactate, electrolytes (sodium, potassium, chloride, calcium,
phosphorus, and magnesium as well as the ionized fraction of calcium and
magnesium), hemodynamic parameters (systemic blood pressure, central venous
pressure, pulmonary arterial pressures, cardiac output, cardiac index, systemic
vascular resistance index), arterial blood gas, GCS, and coagulation studies
(platelet count, prothrombin time, international standardized ratio), were used for
comparison.
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Liver histology was used to quantitate the percentage of necrosis. Post-MARS
liver histology on the native liver, obtained at the time of LTx, and percutaneous
liver biopsies, performed after recovery from the acute event for patients # 6 and
# 7 (those recovered without LTx), was used for comparison with pre-MARS
liver histology. Patient # 1 died before transplantation, autopsy consent was
denied; therefore, post-MARS liver histology for patient #1 was not available for
this study.
Data are presented as mean ± standard deviation. Blood samples for laboratory
tests were collected immediately before and immediately after each MARS
session.

RESULTS
Six patients (85.7%) survived to be discharged from the hospital and they are all
alive and well 15 months after the last MARS session. One patient (14.2%) died
of brain herniation while our team was recovering a liver from an organ donor.
Four patients (57%) were successfully bridged, using MARS, to LTx, and 2
(28.5%) recovered fully without transplantation.
Biochemical effect of MARS
Pre and post MARS serum electrolytes concentration remained remarkably stable
(data not shown).
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Hypoglycemia is common in FHF being due to altered gluconeogenesis in the
failing liver with inadequate hepatic uptake of insulin, heading to increased
peripheral insulin levels [22]. In our series patients treated with MARS showed
remarkable stable blood glucose during treatments (data not shown).
Total bilirubin (Tab. 2), transaminases, gamma-glutamyl transpeptidase, and
ammonia, as previously reported [1, 3], all improved with MARS (data not
shown).
Molecular adsorbent recirculating system reduced, in FHF, the arterial blood
lactate level (Fig. 2).
Effect of MARS on mental status
Those patients that recovered fully without LTx (patients # 6, and 7 of table 1)
showed a steady improvement in GCS after each MARS sessions (Fig. 1). Patient
# 5 of table 1, also, had a significant improvement in GCS after the first MARS
session (Fig. 1); however, at the time of LTx liver necrosis was > 95% (Tab. 3).
Hemodynamic effect of MARS
Patients with FHF tend to be hemodynamically unstable with a low systemic
vascular resistance index and a hyperdinamic circulation [30]. None of the
patients treated in our series, required vasopressors infusion before transplantation
and all remained hemodynamically stable throughout MARS treatment.
Amelioration of the hyperdynamic state, was supported by elevation of systemic
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vascular resistance index, mean arterial pressure, and reduced cardiac index (Fig.
3).
Effect of MARS on gas exchange
Pre and post MARS blood gas remained remarkable stable (data not shown).
Histological effect of MARS
No signs indicative of MARS affecting liver histology were noted when pre and
post MARS liver specimens where compared in the patients who underwent LTx
(Tab. 3: comparison is between histology at the time of the trans-jugular liver
biopsy and histology on the explanted liver). Four out of 5 patients who
underwent LTx showed at the trans-jugular liver biopsy 80% or more liver
necrosis (Tab. 3). Patients # 6 and # 7 (those recovered without LTx) showed 50
% liver necrosis at the admission to the hospital and absence of necrosis at
recovery following the last MARS treatment (Tab. 3).
Effect of MARS on blood coagulations
All patients were coagulophatic at admission and remained as such, despite
aggressive medical correction throughout the stay in the intensive care unit, which
consisted in continuous infusion of fresh frozen plasma at the rate of 30 cc/h.
Although one could postulate that the percentage of necrotic liver tissue correlates
directly to all the commonly seen clinical and biochemical derangements of FHF,
we did not find any relationship between necrosis and prothrombin time (Fig.4).
Prothrombin time before and after MARS is reported in Figure 4.
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DISCUSSION
Paradoxically the major limitation for this study is the availability of LTx which
occurs at various time after treatment commencement; therefore, causing
difficulties in designing scientifically reproducible clinical trials.
We cannot exclude that some of our observed results, in terms of biochemical
omeostasis/hemodynamic stability during treatment of FHF with MARS, may be
secondary to aggressive medical management in the intensive care unit, preceding
transplantation. However, there are proven effects, in different model, of MARS
ameliorating parameters not otherwise influenced by medical therapy, such as
total bilirubin [1, 3], and blood lactate levels [24]. The liver is the principal organ
for lactate metabolism, accounting for 50% of whole body lactate clearance and
utilization, and hence participates in the regulation of serum lactate concentrations
[25-26]. Moreover, in the LTx literature, with both cadaveric and living donor, it
has been demonstrated that the rate of lactate elimination after reperfusion of the
transplanted liver, represents one of the most sensitive and reliable indicators of
hepatic graft function [27-29]. Therefore, we believe that the decrease lactate
level during MARS treatment of patients with FHF indicates improvement (Fig.
2). It is uncertain whether, in our series, MARS is responsible for the observed
decreased transaminases, because normalization of liver enzymes in the late phase
of FHF is typically seen after massive liver necrosis.
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However, it appears that the degree of liver necrosis, GCS, and timing in MARS
commencement may play a role in the outcome of FHF.
In patient # 5 we observed GCS improvement after MARS commencement (Fig.
1), despite ongoing liver necrosis (more then 95% in the explanted liver, table 2).
The same was also observed in patients # 6 and # 7 (those recovered without LTx)
(Fig. 1). We believe that the common denominator for these three patients was
the 50% liver necrosis at the time of MARS commencement. During FHF, coma
is the antecedent of brain herniation and the various degree of mental status
changes observed are, in fact, strictly related to the amount of death liver cells and
the consequent toxins load present in the blood stream [11, 22, 27]. There is
multiple evidence that MARS is able to remove those toxins [1, 3]; therefore,
based on our data, we postulate that if MARS is started before liver necrosis
exceeds 50%, brain herniation can be delayed.
A common criticism to trans-jugular liver biopsy in course of FHF is that it
represents a random liver biopsy and as such it does not reflect the real percentage
of liver necrosis present in the whole liver. However, 80% of the patients in our
series who were transplanted (patients numbered 1 to 4, table 3) showed a
sensitive correlation between pre and post transplant amount of liver necrosis.
Therefore, we believe that the percentage of liver necrosis seen at the transjugular liver biopsy should be used as a clinical guidance to transplantation. We
did not expect any histological change after MARS because of the very few
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treatment sessions and the short time allowed between the histological
observations. For other reasons (few MARS sessions and long interval between
histological observations) we believe that the absence of necrosis in the postMARS liver histology for patients # 6 and # 7 was not a consequence of MARS
treatment. It was expression of healing from FHF.
Obviously, each patient of our series was treated with a different number of
MARS sessions because suitable organ donors became available at different times
during MARS treatment for the different patients. Nonetheless, in our small
series, MARS was found to be safe and efficacious in maintaining stability in
patients diagnosed with FHF and awaiting LTx. Our result suggest that MARS
delayed central nervous system catastrophe by clearing the toxins load typical of
FHF, thus allowing more time for successful bridging to LTx.
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N

Sex/age

Diagnosis

Outcome/# of

Follow-

Total

AST

ALT

GT

Albumin

PT

MARS

up days

bilirubin

IU/L

IU/L

IU/L

gr.

%

sessions

mg/dl

1

F/30

FHF/HBV

Died/2

0

7.41

789

2223

44

3.5

28

2

F/29

FHF/HBV

Alive-

820

6.97

289

1120

25

3.4

28

393

13.13

209

254

48

3.8

30

366

11.65

1239

1986

60

3

38.6

218

17.01

749

1519

51

3

39.6

transplanted/4
3

4

F/22

F/51

FHF/

Alive-

nimesulide

transplanted/1

FHF/HBV

Alivetransplanted/1

5

F/61

FHF/HBV

Alivetransplanted/4

6

F/41

FHF/HBV

Alive/4

184

9.94

455

1730

51

3.1

30

7

M/50

FHF/HBV

Alive/5

180

12.08

638

2308

30

2.8

24.1

Table 1: PATIENT AND LABORATORY DATA AT HOSPITAL ADMISSION

Footnotes:
AST:

Aspartate aminotransferase.

ALT:

Alanine aminotransferase.

GT:

Gamma-glutamyl transpeptidase.

PT:

Prothrombin time

FHF:

Fulminant Hepatic Failure

HBV:

Hepatitis B Virus
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Table 2: CHANGE IN TOTAL BILIRUBIN
Patient

Pre-MARS

Post-MARS

Post-MARS

Post-MARS

Post-MARS

number

total

session #1

session #2

session #3

session #4

bilirubin

total

total

total

total

mg/dl

bilirubin

bilirubin

bilirubin

bilirubin

mg/dl

mg/dl

mg/dl

mg/dl

1

7.41

8.48

8.91

8.14

7.31

2

6.97

8.33

7.88

6.78

6.72

3

13.13

10.06

11.29

-

-

4

11.65

10.83

-

-

-

5

17.01

12.17

-

-

-

6

9.94

8.10

-

-

-

7

12.08

12.03

-

-

-
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Table 3: PRE AND POST MARS LIVER HISTOLOGY
Patient number Pre-MARS necrosis Post-MARS necrosis
1

80%

n/a

2

100% (massive)

100% (massive)

3

95 %

90%

4

95%

100% (massive)

5

50%

> 95% (submassive)

6

50%

0%

7

50%

0%
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Correlation between GCS and necrosis during MARS

Figure 1 legend:
Glasgow Coma Scale is represented by bars. The percentage of liver necrosis is
represented by lines. Each group of bars refers to a single patient. The first bar,
for each patient, identifies the pre-MARS GCS, the following bars of each group
represent GCS after each MARS session up to three sessions. The line with a
triangular dot represents the percentage of liver necrosis before MARS
commencement. The line with the quadrate dot represent the percentage of liver
necrosis on the explanted liver or (for patient #6 and # 7), at recovery after the
acute event.

Footnotes:
GCS:

Glasgow Coma Scale

MARS:

Molecular Adsorbent Recirculating System

Pt:

Patient

T:

Treatment
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Pattern of arterial lactate during MARS in FHF

Figure 2 legend:
The x axis represents the mean arterial lactate concentration in mmol/L, whereas
the y axis represents the different MARS sessions.

Footnotes:
MARS:

Molecular Adsorbent Recirculating System

FHF:

Fulminant Hepatic Failure
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CO, CI and SVRI during MARS in FHF

Figure 3 legend:
Mean cardiac output and cardiac index are represented by bars of different color.
Their unit of measure is L/min and is reported on the left side of the figure. Mean
systemic vascular resistance index is represented by a line. Its unit of measure is
dynes/cm/m2 and is reported on the right side of the figure. The first set of bars
represents pre-MARS values, whereas the following sets represent post-MARS
values from session 1 to 4.

Footnotes:
CO:

Cardiac output

CI:

Cardiac index

SVRI: Systemic vascular resistance index
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Correlation between PT and necrosis during MARS

Figure 4 legend:
Bars represent pre and post-MARS percentage of liver necrosis whereas lines
indicate the prothrombin time. The triangular dot represent pre-MARS
prothrombin time, the X dot represent post-MARS prothrombin time.

Footnotes:
PT:

Prothrombin Time

Pt:

Patient

T:

Treatment
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CO,CI and SVRI during MARS in FHF
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